News articles about Trinity Biotech (NASDAQ:TRIB) have been trending positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Trinity Biotech earned a news sentiment score of 0.36 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.9855874345972 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Trinity Biotech (TRIB) opened at $5.33 on Friday. The stock has a market capitalization of $128.14, a price-to-earnings ratio of -1.47 and a beta of 1.41. The company has a quick ratio of 3.77, a current ratio of 5.16 and a debt-to-equity ratio of 0.90. Trinity Biotech has a 12 month low of $4.22 and a 12 month high of $7.20.
Trinity Biotech (NASDAQ:TRIB) last issued its quarterly earnings data on Thursday, October 26th. The company reported $0.06 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.03. The firm had revenue of $25.60 million during the quarter, compared to analyst estimates of $25.52 million. Trinity Biotech had a positive return on equity of 5.87% and a negative net margin of 100.00%. equities analysts expect that Trinity Biotech will post 0.06 earnings per share for the current fiscal year.
Separately, Zacks Investment Research upgraded Trinity Biotech from a “sell” rating to a “hold” rating in a research note on Wednesday, December 27th.
Trinity Biotech Company Profile
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.